Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis
Involving Twelve Case-Control Studies
#MMPMID27031235
Dong W
; Gong M
; Shi Z
; Xiao J
; Zhang J
; Peng J
PLoS One
2016[]; 11
(3
): e0152448
PMID27031235
show ga
Programmed cell death-1 (PD-1) plays an important inhibitory role in anti-tumor
responses, so it is considered as a powerful candidate gene for individual's
genetic susceptibility to cancer. Recently, some epidemiological studies have
evaluated the association between PD-1 polymorphisms and cancer risk. However,
the results of the studies are conflicting. Therefore, a meta-analysis was
performed. We identified all studies reporting the relationship between PD-1
polymorphisms and cancers by electronically searches. According to the inclusion
criteria and the quality assessment of Newcastle-Ottawa Scale (NOS), only high
quality studies were included. A total of twelve relevant studies involving 5,206
cases and 5,174 controls were recruited. For PD-1.5 (rs2227981) polymorphism,
significantly decreased cancer risks were obtained among overall population,
Asians subgroup and population-based subgroup both in TT vs. CC and TT vs. CT+CC
genetic models. In addition, a similar result was also found in T vs. C allele
for overall population. However, there were no significant associations between
either PD-1.9 (rs2227982) or PD-1 rs7421861 polymorphisms and cancer risks in all
genetic models and alleles. For PD-1.3 (rs11568821) polymorphism, we found
different cancer susceptibilities between GA vs. GG and AA vs. AG+GG genetic
models, and no associations between AA vs. GG, AA+AG vs. GG genetic models or A
vs. G allele and cancer risks. In general, our results firstly indicated that
PD-1.5 (rs2227981) polymorphism is associated a strongly decreased risk of
cancers. Additional epidemiological studies are needed to confirm our findings.
free
free
free
